Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBT Margin (2016 - 2025)

Historic EBT Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 86.15%.

  • China Pharma Holdings' EBT Margin rose 154600.0% to 86.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.72%, marking a year-over-year increase of 68500.0%. This contributed to the annual value of 104.58% for FY2024, which is 606700.0% down from last year.
  • Latest data reveals that China Pharma Holdings reported EBT Margin of 86.15% as of Q3 2025, which was up 154600.0% from 51.51% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' EBT Margin registered a high of 24.28% during Q1 2023, and its lowest value of 155.48% during Q2 2024.
  • Moreover, its 5-year median value for EBT Margin was 54.02% (2023), whereas its average is 61.34%.
  • Per our database at Business Quant, China Pharma Holdings' EBT Margin plummeted by -1014700bps in 2024 and then surged by 1039700bps in 2025.
  • Over the past 5 years, China Pharma Holdings' EBT Margin (Quarter) stood at 33.94% in 2021, then dropped by -28bps to 43.28% in 2022, then crashed by -32bps to 57.32% in 2023, then plummeted by -88bps to 107.98% in 2024, then grew by 20bps to 86.15% in 2025.
  • Its EBT Margin was 86.15% in Q3 2025, compared to 51.51% in Q2 2025 and 69.13% in Q1 2025.